The German Spondyloarthritis Inception cohort (GESPIC) was started 2000 as a prospective, longitudinal, multicentre, nationwide study in Germany on patients with early SpA including ankylosing spondylitis (AS, also known as radiographic axial spondyloarthritis) and non-radiographic axial SpA. The objectives of GESPIC are to learn about the course of SpA during the very early stage of the disease, to appropriately assess the outcome including radiographic progression of patients after several years of follow-up, to identify outcome predictors, to assess quality of life, function, and costs (direct and indirect costs). GESPIC has been recently expanded to recruit patients with other forms of SpA / conditions associated with SpA: acute anterior uveitis, Crohn's disease as well as with psoriasis / axial psoriatic arthritis.
Patients with definite diagnosis of axial spondyloarthritis or juvenile spondyloarthritis.
Patients with definite diagnosis of Crohn's disease.
Patients with definite diagnosis of acute anterior uveitis.
Patients with definite diagnosis of psoriatic arthritis with axial involvement.
None
Patients included in GESPIC are required to have a definite clinical diagnosis of axial SpA / juvenile SpA (currently only adult patients with radiographic axial SpA = ankylosing spondylitis - AS are recruited) or a definite diagnosis of Crohn's disease or a definite diagnosis of acute anterior uveitis or a definite diagnosis of psoriatic arthritis with axial involvement.
Cohort
Prospective
Not listed
6
Trial groupsSee each trial group below.
Click on the lead sponsor to view all of their trials.
Charite University, Berlin, Germany
Lead sponsor
German Federal Ministry of Education and Research
Collaborator
AbbVie
Collaborator
Amgen
Collaborator
Centocor, Inc.
Collaborator
Schering-Plough
Collaborator
Wyeth is now a wholly owned subsidiary of Pfizer
Collaborator
Berlin Institute of Health
Collaborator
Novartis
Collaborator
UCB Pharma
Collaborator
